Lipocine announced an exclusive supply and distribution agreement with Pharmalink to commercialize Tlando, its oral testosterone replacement therapy, in the Gulf Cooperation Council countries consisting of Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman. Under the terms of the agreement, Lipocine received an upfront payment from Pharmalink and, upon Marketing Authorizations in individual GCC countries, Lipocine will provide Tlando drug product to Pharmalink at an agreed transfer price. Pharmalink will have the exclusive rights to Tlando throughout the GCC region and will be responsible for promotion, distribution and sale of the product in the territory.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LPCN:
